Cytochrome P450 2C19 polymorphism and clopidogrel after MI

被引：2
|
作者：
Ramaraj, Radhakrishnan [1 ]
机构：
[1] Univ Arizona, Coll Med, Dept Internal Med, Tucson, AZ 85724 USA
来源：
LANCET | 2009年 / 373卷 / 9670期
关键词：
TRIAL;
D O I：
10.1016/S0140-6736(09)60681-4
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1172 / 1172
页数：1
相关论文
共 42 条
  • [41] Impact of CYP2C19 Genetic Testing on Provider Prescribing Patterns for Antiplatelet Therapy After Acute Coronary Syndromes and Percutaneous Coronary Intervention
    Desai, Nihar R.
    Canestaro, William J.
    Kyrychenko, Pavlo
    Chaplin, Donald
    Martell, Lori A.
    Brennan, Troyen
    Matlin, Olga S.
    Choudhry, Niteesh K.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2013, 6 (06): : 694 - +
  • [42] Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Noncompliance, Diet, Smoking, Co-Medications (Including Proton Pump Inhibitors), and Pre-Existent Variability in Platelet Function
    Frelinger, Andrew L., III
    Bhatt, Deepak L.
    Lee, Ronald D.
    Mulford, Darcy J.
    Wu, Jingtao
    Nudurupati, Sai
    Nigam, Anu
    Lampa, Michael
    Brooks, Julie K.
    Barnard, Marc R.
    Michelson, Alan D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (08) : 872 - 879
12345